Johnson & Johnson: Aspects To Consider After Acquiring Abiomed


  • JNJ’s acquisition of Abiomed increases the prospects of the company advancing innovation in both Medtech and the pharmaceutical business.
  • Sales of JNJ’s pharmaceuticals were highest in the nine months leading to October 2, 2022, at $39.4 billion while consumer health was least at $11.1 billion, a decline of 1.1%.
  • In the 9 months leading to October 2, 2022, sales in JNJ’s Medtech segment stood at $20.7 billion an increase of 2.2% (YoY).

he modern architecture of business center of Johnson and Johnson, Allschwil


Johnson & Johnson (NYSE:JNJ) closed its acquisition of Abiomed (ABMD) on December 22, 2022. Abiomed, a leading manufacturer of heart pump solutions now forms part of JNJ’s Medtech. JNJ’s share price has risen 5.49% (YoY) with the global health giant set

Patient performance against revenue progression for Abiomed


Impella's revenue numbers


JNJ's Medtech sales

Johnson & Johnson

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Leave a Reply

Your email address will not be published. Required fields are marked *